retatrutide ly3437943 glp-1 gip glucagon receptor agonist just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric From Obesity to Metabolic Health:
Description
Preprint at arXiv (2023)
Diabetes Care 37, 27632773
A study published in JAMA Ophthalmology in July 2024 found that individuals taking glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications may be at an increased risk for developing vision problems
For example, exendin-based GLP-1 analogues have an alanine to glutamic acid substitution in the second position [40]
The process by which -cells release insulin in response to glucose and GLP-1
However, compliant weight loss drugs are extremely scarce in the face of strong demand for weight loss
